• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

错配修复缺陷表型是老年结直肠癌患者的预后因素。

Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients.

机构信息

Gastroenterology, Avicenne Hospital, APHP, Université Paris 13, Bobigny, France.

出版信息

Dig Liver Dis. 2013 Mar;45(3):245-50. doi: 10.1016/j.dld.2012.09.013. Epub 2012 Oct 24.

DOI:10.1016/j.dld.2012.09.013
PMID:23102497
Abstract

OBJECTIVE

About 15% of colorectal adenocarcinomas have a deficient DNA mismatch repair phenotype. The frequency of deficient DNA mismatch repair tumours increases with age due to the hypermethylation of hMLH1 promoter. The study aimed to determine the prognostic value of deficient DNA mismatch repair phenotype in elderly patients.

DESIGN

Mismatch repair phenotype was retrospectively determined by molecular analysis in consecutive resected colorectal adenocarcinoma specimens from patients over 75 years of age from 4 Oncology centres.

RESULTS

231 patients (median age: 81, range: 75-100) were enrolled from 2005 to 2008. Mean prevalence of deficient DNA mismatch repair phenotype was 22.5%, and 36% for patients over 85 years. Deficient DNA mismatch repair status was significantly associated with older age, female sex, proximal colon primary and high grade tumour. For stage II tumours no deficient DNA mismatch repair tumours had a recurrence at end of follow-up compared to 17% for tumours with proficient phenotype. The proficient phenotype status was significantly associated with worse age-adjusted overall survival [HR 2.60; 95% CI 1.05-6.44; p=0.039]. For stage III tumours a trend for less recurrence was observed for deficient DNA mismatch repair phenotype (16%) compared to proficient phenotype (36%).

CONCLUSION

deficient DNA mismatch repair phenotype is a prognostic factor in stage II colorectal tumour in elderly patients. Our results suggest that mismatch repair phenotype should be taken in consideration for adjuvant chemotherapy decision in elderly patients.

摘要

目的

约 15%的结直肠腺癌存在 DNA 错配修复缺陷表型。由于 hMLH1 启动子的高甲基化,DNA 错配修复缺陷肿瘤的频率随年龄增长而增加。本研究旨在确定 DNA 错配修复缺陷表型在老年患者中的预后价值。

设计

通过分子分析,回顾性确定来自 4 个肿瘤中心 75 岁以上连续切除的结直肠腺癌标本中的错配修复表型。

结果

2005 年至 2008 年间共纳入 231 例患者(中位年龄:81 岁,范围:75-100 岁)。DNA 错配修复缺陷表型的平均患病率为 22.5%,85 岁以上患者为 36%。DNA 错配修复缺陷状态与年龄较大、女性、近端结肠原发灶和高级别肿瘤显著相关。对于 II 期肿瘤,在随访结束时,无缺陷 DNA 错配修复肿瘤复发,而表型良好的肿瘤复发率为 17%。表型良好与年龄调整后的总生存显著相关[HR 2.60;95%CI 1.05-6.44;p=0.039]。对于 III 期肿瘤,缺陷 DNA 错配修复表型(16%)的复发率低于表型良好(36%),这一趋势具有统计学意义。

结论

在老年患者的 II 期结直肠肿瘤中,DNA 错配修复缺陷表型是一个预后因素。我们的结果表明,在老年患者中,应考虑错配修复表型来决定辅助化疗。

相似文献

1
Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients.错配修复缺陷表型是老年结直肠癌患者的预后因素。
Dig Liver Dis. 2013 Mar;45(3):245-50. doi: 10.1016/j.dld.2012.09.013. Epub 2012 Oct 24.
2
Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients.肿瘤内芽殖作为微卫星稳定型和微卫星不稳定型结直肠癌患者肿瘤进展的一个潜在参数。
Hum Pathol. 2011 Dec;42(12):1833-40. doi: 10.1016/j.humpath.2011.02.010. Epub 2011 Jun 12.
3
Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.尿激酶型纤溶酶原激活剂是错配修复功能正常的结直肠癌侵袭性表型的标志物和独立预后因素。
Hum Pathol. 2010 Jan;41(1):70-8. doi: 10.1016/j.humpath.2009.05.013. Epub 2009 Sep 8.
4
Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.错配修复状态在预测结直肠癌辅助氟尿嘧啶化疗获益中的作用
Gut. 2006 Jun;55(6):848-55. doi: 10.1136/gut.2005.073015. Epub 2005 Nov 18.
5
Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency.基于错配修复缺陷对未选择的结直肠肿瘤进行分类的临床实践策略。
Colorectal Dis. 2008 Jun;10(5):490-7. doi: 10.1111/j.1463-1318.2007.01378.x. Epub 2007 Sep 13.
6
Tumor Grade Is Prognostically Relevant Among Mismatch Repair Deficient Colorectal Carcinomas.错配修复缺陷型结直肠癌中肿瘤分级具有预后相关性。
Am J Surg Pathol. 2018 Dec;42(12):1686-1692. doi: 10.1097/PAS.0000000000001145.
7
Prognostic impact of β-2-microglobulin expression in colorectal cancers stratified by mismatch repair status.β-2-微球蛋白表达在结直肠癌中按错配修复状态分层的预后影响。
J Clin Pathol. 2012 Nov;65(11):996-1002. doi: 10.1136/jclinpath-2012-200742. Epub 2012 Aug 2.
8
The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.5-氟尿嘧啶辅助化疗在结直肠癌中的疗效取决于错配修复状态。
Eur J Cancer. 2009 Feb;45(3):365-73. doi: 10.1016/j.ejca.2008.07.016. Epub 2008 Aug 21.
9
Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.错配修复缺陷状态作为接受辅助 FOLFOX 化疗的 III 期结肠癌患者无病生存的预后生物标志物。
Clin Cancer Res. 2011 Dec 1;17(23):7470-8. doi: 10.1158/1078-0432.CCR-11-1048. Epub 2011 Oct 13.
10
Molecular biology from bench-to-bedside - which colorectal cancer patients should be referred for genetic counselling and risk assessment.从实验室到临床的分子生物学——哪些结直肠癌患者应转介进行遗传咨询和风险评估。
Eur J Cancer. 2010 Jul;46(10):1823-8. doi: 10.1016/j.ejca.2010.03.016. Epub 2010 Apr 21.

引用本文的文献

1
Polyphenol Intake in Elderly Patients: A Novel Approach to Counteract Colorectal Cancer Risk?老年患者的多酚摄入量:一种对抗结直肠癌风险的新方法?
Int J Mol Sci. 2025 Mar 11;26(6):2497. doi: 10.3390/ijms26062497.
2
Risk of Lymph Node Metastasis in T2 Colon Cancer: A Nationwide Population-Based Cohort Study.T2期结肠癌淋巴结转移风险:一项基于全国人群的队列研究。
Ann Surg Oncol. 2025 May;32(5):3078-3088. doi: 10.1245/s10434-025-16921-w. Epub 2025 Jan 23.
3
Aging and cancer: Clinical role of tumor markers in the geriatric population (Review).
衰老与癌症:肿瘤标志物在老年人群中的临床作用(综述)
Med Int (Lond). 2024 Mar 6;4(3):21. doi: 10.3892/mi.2024.145. eCollection 2024 May-Jun.
4
Navigating through novelties concerning mCRC treatment-the role of immunotherapy, chemotherapy, and targeted therapy in mCRC.探索转移性结直肠癌(mCRC)治疗的新进展——免疫疗法、化疗和靶向疗法在mCRC中的作用
Front Surg. 2024 Jun 14;11:1398289. doi: 10.3389/fsurg.2024.1398289. eCollection 2024.
5
Lymphatic spread patterns in young versus elderly patients with stage III colon cancer.年轻和老年 III 期结肠癌患者的淋巴扩散模式。
BJS Open. 2024 May 8;8(3). doi: 10.1093/bjsopen/zrae036.
6
Guidance for Treating the Older Adults with Colorectal Cancer.老年人结直肠癌治疗指南。
Curr Treat Options Oncol. 2023 Jun;24(6):644-666. doi: 10.1007/s11864-023-01071-6. Epub 2023 Apr 13.
7
Management of Metastatic Colorectal Carcinoma in Older Adults: Balancing Risks and Benefits of Novel Therapies.老年转移性结直肠癌的管理:平衡新型疗法的风险和获益。
Drugs Aging. 2021 Aug;38(8):639-654. doi: 10.1007/s40266-021-00869-z. Epub 2021 Jun 18.
8
Rate of dissemination and prognosis in early and advanced stage colorectal cancer based on microsatellite instability status: systematic review and meta-analysis.基于微卫星不稳定性状态的早期和晚期结直肠癌的传播率和预后:系统评价和荟萃分析。
Int J Colorectal Dis. 2021 Aug;36(8):1573-1596. doi: 10.1007/s00384-021-03874-1. Epub 2021 Feb 18.
9
Adjuvant Chemotherapy in Elderly Colorectal Cancer Patients.老年结直肠癌患者的辅助化疗
Cancers (Basel). 2020 Aug 14;12(8):2289. doi: 10.3390/cancers12082289.
10
Prognostic Value of Mismatch Repair Genes for Patients With Colorectal Cancer: Meta-Analysis.错配修复基因对结直肠癌患者的预后价值:Meta分析
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818808507. doi: 10.1177/1533033818808507.